Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

World Journal of Oncology - Canada
doi 10.14740/wjon1164
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elmer Press, Inc.

Related search

Pharmacogenetics in Clinical Practice: How Far Have We Come and Where Are We Going?

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2013English

Picosecond Diffraction at the ESRF: How Far Have We Come and Where Are We Going?

AIP Conference Proceedings
AstronomyPhysics
2007English

Liver Transplantation Today: Where We Are Now and Where We Are Going

Liver Transplantation
HepatologyTransplantationSurgery
2018English

Where Have We Been and Where Are We Going?

1998English

Look How Far We Have Come

2014English

Community Education: Where We Have Been and Where We Are Going

Educational Considerations
1974English

ERRATUM: Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency Using Post-Transplantation Cyclophosphamide

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Biogenerics 2007: How Far Have We Come?

Journal of Commercial Biotechnology
BiotechnologyManagement of TechnologyEconomicsEconometricsInnovation
2008English

Infectious Complications After Post‐transplantation Cyclophosphamide and Anti‐thymocyte Globulin‐based Haploidentical Stem Cell Transplantation

British Journal of Haematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy